Ceramide does not mediate the effect of tumour necrosis factor alpha on superoxide generation in human neutrophils.
The effect of tumour necrosis factor alpha (TNF alpha) on superoxide generation in human neutrophils was investigated using the Nitro Blue Tetrazolium reduction assay. TNF alpha stimulated superoxide generation in a time- and concentration-dependent fashion. The maximally effective concentration of TNF alpha for superoxide generation was 10 nM and maximal response was obtained after 15-20 min. The monoclonal antibody (mAb), utr-1, which was raised against the 75 kDa receptor and behaves as an antagonist, had no effect on superoxide generation, but partially inhibited the response to TNF alpha. mAb htr-9, which was raised against the 55 kDa receptor and behaves as an agonist, mimicked the effect of TNF alpha, but with a lower maximal response. As it has been reported that ceramide might act as a second messenger to mediate many of the effects of TNF alpha, the effects of exogenous sphingomyelinase and the cell-permeable ceramide analogue, C2- ceramide, on production of superoxide anions, induction of priming in response to formylmethionyl-leucyl-phenylalanine, and cell-shape change were examined. Neither sphingomyelinase nor C2-ceramide mimicked the effect of TNF alpha. Ceramide is converted into ceramide 1-phosphate by ceramide kinase and we have measured levels of this metabolite to clarify the effect of TNF alpha on sphingomyelinase activity in neutrophils. Although exogenous sphingomyelinase increased the amount of ceramide 1-phosphate in a time-dependent manner, and C2-ceramide was rapidly converted into C2-ceramide phosphate, TNF alpha had no effect on the level of ceramide 1-phosphate. These results suggest that TNF alpha stimulates superoxide generation through both the 55 kDa and 75 kDa receptors, but that ceramide does not act as an intracellular mediator for TNF alpha in human neutrophils.
Yanaga
F
F
Department of Pharmacology, Oxford University, U.K.
Watson
S P
SP
D000251:Adenosine Triphosphatases / Q000032:analysis / Q000378:metabolism*; D000328:Adult; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D002518:Ceramides / Q000494:pharmacology*; D006801:Humans; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism*; D009580:Nitroblue Tetrazolium; D010084:Oxidation-Reduction; D018124:Receptors, Tumor Necrosis Factor / Q000276:immunology / Q000502:physiology; D013108:Sphingomyelin Phosphodiesterase / Q000494:pharmacology; D013481:Superoxides / Q000097:blood*; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; D002518:Ceramides; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D013481:Superoxides; D009580:Nitroblue Tetrazolium; D009240:N-Formylmethionine Leucyl-Phenylalanine; D013108:Sphingomyelin Phosphodiesterase; D000251:Adenosine Triphosphatases